0VF9 Stock Overview
A late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Resverlogix Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.065 |
| 52 Week High | CA$0.10 |
| 52 Week Low | CA$0.065 |
| Beta | 0.69 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0VF9 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -4.2% | -0.4% |
| 1Y | n/a | -27.9% | 6.1% |
Return vs Industry: Insufficient data to determine how 0VF9 performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0VF9 performed against the UK Market.
Price Volatility
| 0VF9 volatility | |
|---|---|
| 0VF9 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.8% |
Stable Share Price: 0VF9 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0VF9's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 19 | Don McCaffrey | www.resverlogix.com |
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company’s lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications.
Resverlogix Corp. Fundamentals Summary
| 0VF9 fundamental statistics | |
|---|---|
| Market cap | CA$15.11m |
| Earnings (TTM) | -CA$14.01m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.1x
P/E RatioIs 0VF9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0VF9 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$10.25m |
| Earnings | -US$10.25m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.037 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -78.3% |
How did 0VF9 perform over the long term?
See historical performance and comparison